AEGERION PHARMACEUTICALS LIMITED
Get an alert when AEGERION PHARMACEUTICALS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-07-05 (in 2mo)
Last made up 2025-06-21
Watchouts
None on the register
Cash
£8M
+647.2% vs 2023
Net assets
£44M
+6.2% vs 2023
Employees
—
Average over period
Profit before tax
£3M
+265.4% vs 2023
Net assets
2-year trend · vs Consumer Discretionary median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £1,968,347 | £2,288,795 | |
| Operating profit | -£1,562,251 | £2,583,766 | |
| Profit before tax | -£1,562,251 | £2,583,766 | |
| Net profit | -£1,562,251 | £2,583,766 | |
| Cash | £1,118,518 | £8,357,228 | |
| Total assets less current liabilities | £41,818,167 | £44,401,933 | |
| Net assets | £41,818,167 | £44,401,933 | |
| Equity | £41,818,167 | £44,401,933 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -79.4% | 112.9% | |
| Net margin | -79.4% | 112.9% | |
| Return on capital employed | -3.7% | 5.8% | |
| Current ratio | 2.60x | 9.02x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Deloitte Ireland LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The financial statements of the Company are prepared on a going concern basis on the basis that management have no intention of either liquidating the entity or ceasing trading, or has no realistic alternative but to do so. Having considered the Company's current financial position and the Group's projections, the Directors believe that the Company will be able to continue in operational existence for at least the next 12 months from the date of approval of these financial statements and that it is appropriate to continue to prepare the financial statements on a going concern basis.”
Group structure
- AEGERION PHARMACEUTICALS LIMITED · parent
- Amryt Turkey ILac Ticaret Limited Sirketi 100%
Significant events
- “During 2023, the shareholding of Amryt Pharmaceuticals SAS in France and Aegerion Pharmaceuticals SL was sold to fellow Chiesi affiliates and Aegerion Pharmaceuticals SRL and Aegerion Pharmaceuticals SARL were liquidated.”
- “During 2024, the shareholding of Amryt Pharma GmbH was sold to a fellow Chiesi affiliate and Aegerion Pharmaceuticals BV was liquidated.”
- “Two of the Company's subsidiaries, Aegerion Pharmaceuticals SARL and Aegerion Pharmaceuticals SRL were liquidated during the year ended 31 December 2023.”
- “During the year ended 31 December 2023, the Company's investment in Amryt Pharmaceuticals SAS and Aegerion Pharmaceuticals Spain, S.L. was acquired by fellow Chiesi group affiliates. The disposal of the investments resulted in a gain on disposal, which is recognised in the Statement of Comprehensive Income included in other operating income.”
- “During the year ended 31 December 2024, the Company's investment in Amryt Pharma GmbH was acquired by a fellow Chiesi group affiliate. The disposal of the investment resulted in a gain on disposal, which is recognised in the Statement of Comprehensive Income included in other operating income. Aegerion Pharmaceuticals BV was liquidated effective 25 December 2024.”
- “In February 2022, Amryt secured US$125,000,000 of senior credit facilities from funds managed by the Credit Group of Ares Management Corporation ("Ares"). Amryt used a portion of the proceeds to refinance its previous secured term debt facility. Charges were taken over in the case that the Company is an owner thereof, including, but are not limited to cash and cash equivalents, equipment, fixtures and other goods, intangible assets, intellectual property and inventory as guarantee and collateral for the provision of the debt. The charges were satisfied following the repayment of the debt facility in conjunction with the acquisition of Amryt by Chiesi.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 19 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| WIGGETTS, Matthew Hammond | Secretary | 2023-05-26 | — | — |
| DICKINSON, Andrew Philip | Director | 2023-05-26 | Dec 1970 | British |
| FEELY, Gerard | Director | 2024-09-26 | Jan 1982 | Irish |
| WIGGETTS, Matthew Hammond | Director | 2023-05-26 | May 1972 | British |
Show 19 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| COOK, Anne Marie | Secretary | 2012-06-21 | 2014-05-01 |
| HOGAN, Ailish | Secretary | 2019-09-24 | 2023-05-26 |
| CORPORATION SERVICE COMPANY (UK) LIMITED | Corporate Secretary | 2021-01-04 | 2023-08-01 |
| SISEC LIMITED | Corporate Secretary | 2012-06-21 | 2019-09-24 |
| ALLMOND, David | Director | 2016-07-15 | 2017-03-31 |
| BORIERO, Massimo | Director | 2013-02-21 | 2015-01-16 |
| BOURSIER, Jean-Yves Philippe | Director | 2012-06-21 | 2016-07-15 |
| CHAN, Barbara | Director | 2017-10-01 | 2019-09-24 |
| COOK, Anne Marie | Director | 2012-06-21 | 2014-05-01 |
| GLENNANE, David John | Director | 2019-09-24 | 2023-07-13 |
| HARSHBARGER, Benjamin Scott | Director | 2017-12-18 | 2019-09-24 |
| HARSHBARGER, Benjamin Scott | Director | 2014-05-01 | 2016-07-15 |
| HOGAN, Ailish | Director | 2023-05-26 | 2024-09-26 |
| KIDD, Janet Louise | Director | 2016-07-15 | 2017-12-18 |
| MCEVOY, John | Director | 2019-09-24 | 2023-05-26 |
| ROTHERA, Mark | Director | 2012-06-21 | 2013-02-21 |
| SEEBERGER, David Henrik | Director | 2016-07-15 | 2017-10-01 |
| TRIMMING, Julian William | Director | 2016-07-15 | 2017-10-01 |
| TRIMMING, Julian William | Director | 2014-05-01 | 2014-12-11 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Amryt Pharma Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-09-24 | Active |
| Novelion Therapeutics Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-11-29 | Ceased 2019-09-24 |
| Aegerion Pharmaceuticals, Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2016-11-29 |
Filing timeline
Last 20 of 94 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-09-29 | AA | accounts | Accounts with accounts type full | |
| 2025-09-16 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-07-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-09 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-03 | TM01 | officers | Termination director company with name termination date | |
| 2024-09-05 | AA | accounts | Accounts with accounts type full | |
| 2024-06-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-09-23 | AA | accounts | Accounts with accounts type full | |
| 2023-08-08 | TM02 | officers | Termination secretary company with name termination date | |
| 2023-07-26 | TM01 | officers | Termination director company with name termination date | |
| 2023-07-10 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-06-01 | AP01 | officers | Appoint person director company with name date | |
| 2023-06-01 | AP03 | officers | Appoint person secretary company with name date | |
| 2023-06-01 | TM01 | officers | Termination director company with name termination date | |
| 2023-06-01 | TM02 | officers | Termination secretary company with name termination date | |
| 2023-06-01 | AP01 | officers | Appoint person director company with name date | |
| 2023-06-01 | AP01 | officers | Appoint person director company with name date | |
| 2023-04-19 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2023-04-19 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2022-10-11 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+16.3%
£1,968,347 £2,288,795
-
Cash
+647.2%
£1,118,518 £8,357,228
-
Net assets
+6.2%
£41,818,167 £44,401,933
-
Employees
—
Not reported
-
Operating profit
+265.4%
-£1,562,251 £2,583,766
-
Profit before tax
+265.4%
-£1,562,251 £2,583,766
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers